Destroy user interface control
J Am Acad Dermatol. 2013 Jan 31. pii: S0190-9622(12)01054-7
Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University.
Ladizinski B, Bazakas A, Selim MA, Olsen EA.
Hair Disorders Research and Treatment Center, Duke University Medical Center, Durham, North Carolina.
Frontal fibrosing alopecia (FFA) is a type of scarring hair loss primarily observed in postmenopausal women and characterized by fronto-tempero-parietal hairline recession, perifollicular erythema, and loss of eyebrows. The incidence is unknown, but the number of women presenting with this condition has significantly increased in recent years. No effective therapy has been established.
The purpose of this study is to present pertinent demographic and clinical findings of patients with FFA seen at an academic hair loss clinic and their responses to various therapeutic interventions.
Patients seen at the Duke University Hair Disorders Research and Treatment Center, Durham, NC, between 2004 and 2011 who met FFA inclusion criteria and signed an informed consent form for participation in the Duke University Hair Disorders Research and Treatment Center database were included in this review.
Nineteen female patients with FFA met our inclusion criteria, the majority of whom were white and postmenopausal. A number of treatments, including topical and intralesional steroids, antibiotics, and immunomodulators, were used with disappointing results in most patients. However, the majority of patients
FFA is an increasingly common form of scarring hair loss, but the origin remains unknown. Without clear understanding of the pathogenesis and evolution of this condition, it is not surprising that treatments to date have been minimally or not effective. At our institution, dutasteride was most effective in halting disease progression, although no therapy was associated with significant hair regrowth.
A Hair Growth Enhancing Agent
Biol Pharm Bull. 2008 Mar;31(3):449-53.
t-flavanone, a hair regrowth enhancing active component,decreases TGF-beta2)…..
Sasajima M, et al
t-flavone is a synthetic compound with hair regrowth enhancing activity that is effective against male pattern alopecia.t-Flavanone was designed as a derivative of astilbin, the active hair growth enhancing component of Hypericum perforatum extracts. This study was designed to elucidate the mechanism of hair regrowth enhancement by t-flavanone. We investigated the effects of t-flavanone on transforming growth factor beta (TGF-beta), a known catagen-inducing factor induced in hair papilla cells by male hormone. When t-flavanone was added to cocultures of human hair papilla cells and human keratinocytes, there was no change in the total level of TGF-beta2. However, levels of active TGF-beta2 were reduced, suggesting the involvement oft-flavanone in the activation pathway of TGF-beta2. ….. t-Flavanone is a hair regrowth enhancing component that has a novel mechanism of action which suppresses TGF-beta2 activation, and thereby is expected to treat other types of alopecia in addition to male pattern hair loss.
Edited for hair loss treatment blog use
See these for information about hair loss treatment.
Hair Loss Blog Hair loss blog at md.st
Hair loss blog at peterproctor.com
Hair loss Blog at drproctor.com
How tacrolimus may work in hair loss treatment
Clin Exp Dermatol. 2009 Dec;34(8):e937-40.
Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen.
Wang Y, et al
Tacrolimus has shown promising results in the treatment of various dermatological diseases, including hair loss. ….. In this study, we investigated the effects of topical tacrolimus on anagen in the hair cycle and on the expression of vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) mRNAs in mouse skin. Topical tacrolimus 0.1% ointment was applied to one side of the skin of depilated C57BL/6 mice. snip.. No obvious difference in skin colour, hair cycling or histological features was found between the treated and untreated skin, but the levels of Vegf mRNA and Igf-1 mRNA were markedly decreased in the treated skin in late anagen, compared with those in untreated skin.
:: Next Page >>
Hair Loss and Hair Loss Treatment
| Next >